Edwards Receives FDA Approval for Hemodynamic Monitor
July 2nd, 2014
Edwards Lifesciences Corporation announced today that it has received FDA approval for their hemodynamic monitoring system called ClearSight. The ClearSight system assists medical professionals in obtaining arterial & veneous circulation as well as cardiac parameters through a simple non-invasive test with the finger.
The ClearSight system from Edwards Lifesciencesis is the most advanced non-invasive hemodynamic monitor that amplifies a physician’s access to a patient’s advanced hemodynamic parameters, without complex impediments or invasive procedures. The ClearSight system is connected to a patient by wrapping an inflatable cuff around the finger.The system allows physicians to assess adequate oxygen supply as well as assess how various important parameters related to the patient’s heart. Such information as fluid content, cardiac output and cardiac index lead to preventative care prior to responding once a complication has occurred.
The ClearSight system is already available in CE Mark countries but soon here in the U.S with the late FDA approval.
